TB-500 (Thymosin Beta-4) Nasal Spray
The full-length, N-acetylated 43-residue peptide as a sterile solution in bacteriostatic water, in a metered spray bottle. Made from a peptide lot tested in the manufacturer’s own laboratory, with a certificate.
| Compound | TB-500 (Thymosin β4) N-acetyl thymosin β4, full-length 43-residue peptide |
|---|---|
| CAS number | 77591-33-4 |
| Molecular formula | C212H350N56O78S |
| Theoretical mass | 4963.5 Da |
| Sequence / structure | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH (43 residues; N-acetyl; free C-terminus) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Format | Solution in a metered nasal spray bottle |
Sizes and lots
- 5 mg · 1 bottle — $118.99
- 5 mg · Kit of 10 — $1057.82
Here it comes as a sterile solution in bacteriostatic water, in a metered nasal spray bottle with the concentration printed on the label. Thymosin beta-4 research covers actin regulation and tissue repair in cell and animal studies, while a separate literature looks at whether large molecules can travel from the nose to the brain.
What is in the bottle
The bottle contains the same N-acetyl thymosin beta-4 as the vials and pen, dissolved as a sterile solution in bacteriostatic water with 0.9% benzyl alcohol as a preservative. The label states the peptide amount and concentration, and the safety data sheet puts the peptide at under 10% w/v. Benzyl alcohol carries hazard statements for harm when swallowed or inhaled, serious eye irritation and skin sensitisation. The peptide is not classified.
Store the bottle upright and capped at 2 to 8 °C, out of the light, and never freeze it. General guidance on keeping peptides and peptide solutions is in the peptide storage and stability article.
What the research covers
Thymosin beta-4 binds monomeric actin in a 1:1 complex, which holds a reserve of monomers out of filaments while keeping them on hand for the cell1. Huff and colleagues also noted that it appears outside cells, in plasma and wound fluid, where chemotaxis, angiogenesis and reduced inflammation have been attributed to it, though the mechanism was not known1. A 2012 review summarised repair work in skin, eye, heart and brain, including findings that it lowers myofibroblast numbers and scar formation in wounds, and listed clinical trials as ongoing or planned rather than complete2.
The nasal route raises separate questions, and its literature is not about thymosin beta-4. Lochhead and Thorne reviewed the anatomy of the nose and the pathways that may carry substances from the nasal epithelium to the central nervous system, and described the route as a possible way for large biologics such as proteins to get past the blood-brain barrier, drawing on both preclinical and clinical studies3. None of the references on this page studied thymosin beta-4 delivered through the nose, so how much of a 4963.5 Da peptide crosses the nasal lining, or where it goes, is not established here.
Frequently asked questions
Is the spray the same peptide as the TB-500 vials?
Yes, the same full-length N-acetyl thymosin beta-4 with the 43-residue sequence shown in the specifications. The difference is the form: the vials are freeze-dried powder kept frozen, while the spray is a ready-made solution in bacteriostatic water that is kept cold but never frozen.
How much peptide is in the bottle?
The bottle label gives the peptide amount and concentration. Where a study needs a concentration you choose yourself, the 5 mg and 10 mg vials hold a stated mass of freeze-dried peptide that can be dissolved in whatever volume the work calls for.
Has thymosin beta-4 been studied as a nasal spray?
Not in any paper cited on this page. The nasal delivery review covers proteins and other large biologics in general, and none of the thymosin beta-4 abstracts here mentions the nasal route, so there are no published findings specific to this format to point to.
References
- Huff T, Müller CS, Otto AM, et al. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-20. DOI · PubMed
- Goldstein AL, Hannappel E, Sosne G, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. DOI · PubMed
- Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614-28. DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.